UpdatesPress Release
Piramal Pharma reported Q1 FY27 revenue up 17% to ₹2,270 Cr, and EBITDA surged 72% to ₹285 Cr (12.5% margin). Growth across all segments with improved execution.
Piramal Pharma LimitedPPLPHARMA · Filed with the exchange
CDMO strong, CHG gained ex-US traction, PCH boosted by Power Brands.
No comments yet. Be the first.